Risultati di ricerca
7 nov 2016 · ARNI – SACUBITRIL/VALSARTAN (LCZ696): un nuovo farmaco per lo scompenso cardiaco a funzione sistolica ridotta di Paola Naso e Giorgio Faganello. Nelle prossime settimane sarà disponibile l’associazione di SACUBITRIL/VALSARTAN per la terapia dello scompenso cardiaco sistolico.
Si tratta di una nuova classe di farmaci chiamati ARNI (Angiotensin Receptor Neprilysin Inhibitor). Sacubitril è un profarmaco che, in seguito ad attivazione, si trasforma nel metabolita attivo LBQ657, il quale a sua volta inibisce l’endopeptidasi neprilisina, responsabile della degradazione dei peptidi natriuretici, aumentandone i livelli.
2 mag 2022 · The angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan has multiple beneficial effects on the cardiovascular system [ 1 ]. Sacubitril/valsartan was approved as...
21 lug 2021 · 21 Citations. 8 Altmetric. Metrics. Abstract. Angiotensin receptor-neprilysin inhibitors (ARNIs) are a new class of cardiovascular agents characterized by their dual action on the major...
10 gen 2012 · May, who died in Kitsilano, B.C. on Dec. 13, 2011, was a talented 18-year-old drummer and band leader in 1957 who’s Arni May Orchestra had been chosen to back up Elvis and his four musicians...
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction compared to enalapril, the gold standard angiotensin-converting enzyme inhibitor.
29 apr 2020 · The Prospective Comparison of angiotensin receptor-neprilysin inhigitor (ARNI) with angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial showed that ARNI could change the grim prognosis of patient with HF.
